JP2010511598A5 - - Google Patents

Download PDF

Info

Publication number
JP2010511598A5
JP2010511598A5 JP2009530650A JP2009530650A JP2010511598A5 JP 2010511598 A5 JP2010511598 A5 JP 2010511598A5 JP 2009530650 A JP2009530650 A JP 2009530650A JP 2009530650 A JP2009530650 A JP 2009530650A JP 2010511598 A5 JP2010511598 A5 JP 2010511598A5
Authority
JP
Japan
Prior art keywords
epo
pharmaceutical formulation
polypeptide
drugs
receptor agonist
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2009530650A
Other languages
English (en)
Japanese (ja)
Other versions
JP2010511598A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2007/079964 external-priority patent/WO2008042800A2/en
Publication of JP2010511598A publication Critical patent/JP2010511598A/ja
Publication of JP2010511598A5 publication Critical patent/JP2010511598A5/ja
Pending legal-status Critical Current

Links

JP2009530650A 2006-09-29 2007-09-28 グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途 Pending JP2010511598A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US82754106P 2006-09-29 2006-09-29
PCT/US2007/079964 WO2008042800A2 (en) 2006-09-29 2007-09-28 Human epo receptor agonists, compositions, methods and uses for preventing or treating glucose intolerance related conditions

Publications (2)

Publication Number Publication Date
JP2010511598A JP2010511598A (ja) 2010-04-15
JP2010511598A5 true JP2010511598A5 (enExample) 2010-09-24

Family

ID=39269124

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2009530650A Pending JP2010511598A (ja) 2006-09-29 2007-09-28 グルコース不耐症関連症状を予防若しくは治療するためのヒトｅｐｏ受容体アゴニスト、組成物、方法および用途

Country Status (16)

Country Link
US (1) US20100183592A1 (enExample)
EP (1) EP2109456A2 (enExample)
JP (1) JP2010511598A (enExample)
KR (1) KR20090077935A (enExample)
CN (1) CN101801403A (enExample)
AU (1) AU2007303527A1 (enExample)
BR (1) BRPI0717155A2 (enExample)
CA (1) CA2665037A1 (enExample)
EA (1) EA200970338A3 (enExample)
IL (1) IL197850A0 (enExample)
MX (1) MX2009003441A (enExample)
NZ (1) NZ575824A (enExample)
SG (1) SG175567A1 (enExample)
UA (1) UA98472C2 (enExample)
WO (1) WO2008042800A2 (enExample)
ZA (1) ZA200902916B (enExample)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia
EP2567959B1 (en) 2011-09-12 2014-04-16 Sanofi 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors
AU2011377617B2 (en) * 2011-09-23 2018-03-08 Bluebird Bio, Inc. Improved gene therapy methods
JP6050289B2 (ja) * 2013-07-11 2016-12-21 Ｊｃｒファーマ株式会社 組換え蛋白質高発現細胞株の選択法
CN107998134A (zh) * 2016-11-01 2018-05-08 江苏万邦生化医药股份有限公司 可博美在制备辅助治疗糖尿病足的药物制剂中的应用

Family Cites Families (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7241733B2 (en) * 2002-06-28 2007-07-10 Centocor, Inc. Mammalian EPO mimetic CH1 deleted mimetibodies, compositions, methods and uses
DE10234192B4 (de) * 2002-07-26 2009-11-26 Epoplus Gmbh Co.Kg Verwendung von Erythropoetin
AU2004288831B2 (en) * 2003-11-12 2010-08-26 Phenomix Corporation Heterocyclic boronic acid compounds
JP3930870B2 (ja) * 2004-06-02 2007-06-13 シャープ株式会社 電子写真用二成分現像剤
US20100034819A1 (en) * 2006-03-31 2010-02-11 Centocor Inc. Human epo mimetic hinge core mimetibodies, compositions, methods and uses for preventing or treating glucose intolerance related conditions on renal disease associated anemia

Similar Documents

Publication Publication Date Title
US8993622B2 (en) Antiviral compounds
JP2005512522A5 (enExample)
JP2008525477A5 (enExample)
ES2457041T3 (es) Derivados de N-4-piperidilurea y medicamentos que los contienen como principio activo
ES2755183T3 (es) Compuestos ppar para uso en el tratamiento de enfermedades fibróticas
JP6169079B2 (ja) 徐放のための活性剤の製剤
JP2010534664A5 (enExample)
ES2831049T3 (es) Uso de antagonistas de cxcr4 para tratar síndrome de WHIM, mielocatexis, neutropenia y linfocitopenia
JP2014526441A5 (enExample)
RU2016142690A (ru) Композиции на основе стабилизированных фибронектиновых доменов, способы и области их применения
ES2393324T3 (es) Compuestos y composiciones para administrar principios activos
BR112015005783B1 (pt) Análogos de glucagon
CN101801189A (zh) 用于治疗沙粒病毒感染的抗病毒药
JP2007503451A5 (enExample)
BRPI0812398A2 (pt) domínio variável simples de imunoglobulina anti-vegf, antagonista anti-vegf, domínio variável simples de imunoglobulina resistente à protease, uso do antagonista vegf, método para a dispensação oral ou dispensação de um medicamento ao trato gi de um paciente ou ao pulmão ou tecido pulmonar ou olho de um paciente, dispositivo de dispensação pulmonar, formulação oral, ligando específico duplo, ácido nucleico isolado ou recombinante, vetor, célula hospedeira, método para produzir polipeptídeo, composição farmacêutica, polipeptídeo, e, proteína de fusão
CA2492649A1 (en) Therapies for renal failure using interferon-.beta.
JP2006528982A (ja) ペプチドｙｙおよびｐｙｙ作用薬の送達用組成物
JP2013535471A5 (enExample)
RU2013120135A (ru) Глюкозозависимые инсулинотропные пептидные аналоги
JP2009535330A5 (enExample)
CN111417647A (zh) 新型senolytic肽
TW202204390A (zh) 長效酪酪肽(pyy)類似物及使用方法
JP2014504601A5 (enExample)
KR20150070180A (ko) 근위축성 측삭 경화증 치료제
ES2892957T3 (es) Composiciones y métodos de modulación de la actividad de AT2R